Circulating myostatin as a biomarker of muscle mass and strength in individuals with cancer or obesity
Open Access
- 31 May 2024
- journal article
- research article
- Published by Elsevier in Clinical Nutrition
- Vol. 43 (7) , 1800-1808
Abstract
No abstract availableKeywords
Funding Information
- FNRS
This publication has 53 references indexed in Scilit:
- Weight loss between glucagon‐like peptide‐1 receptor agonists and bariatric surgery in adults with obesity: A systematic review and meta‐analysisObesity, 2022
- Validation of a description of sarcopenic obesity defined as excess adiposity and low lean mass relative to adiposityJournal of Cachexia, Sarcopenia and Muscle, 2020
- Rate and Determinants of Excessive Fat-Free Mass Loss After Bariatric SurgeryObesity Surgery, 2020
- Fat‐Free Mass and Skeletal Muscle Mass Five Years After Bariatric SurgeryObesity, 2018
- Pitfalls in the measurement of muscle mass: a need for a reference standardJournal of Cachexia, Sarcopenia and Muscle, 2018
- Biomarkers of cancer cachexiaClinical Biochemistry, 2017
- Sarcopenic obesity or obese sarcopenia: A cross talk between age-associated adipose tissue and skeletal muscle inflammation as a main mechanism of the pathogenesisAgeing Research Reviews, 2017
- Factors Associated with the Serum Myostatin Level in Patients Undergoing Peritoneal Dialysis: Potential Effects of Skeletal Muscle Mass and Vitamin D Receptor Activator UseCalcified Tissue International, 2016
- Assessing appendicular skeletal muscle mass with bioelectrical impedance analysis in free-living Caucasian older adultsClinical Nutrition, 2015
- Clinical outcomes related to muscle mass in humans with cancer and catabolic illnessesThe International Journal of Biochemistry & Cell Biology, 2013